EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›AZTR

AZTR

Azitra, Inc.

Last earnings -1.4% on 2026-05-13

Sell
$0.17
▲ +0.78%
$0.17▼ -90.37%
over 1Y
L $0.14EODHDH $1.77
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.8%
1W+0.6%
1M-19.3%
3M-30.4%
YTD-40.1%
1Y-90.4%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Sell
Quality
F
Valuation
Fair value
Filings
Watch
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy

Conservative balance sheet (liabilities/equity 0.56x); but revenue fell -100.0% YoY.

Revenue (FY2025) $0.00 · FY2025

Azitra, Inc. shows $0.00 in FY2025 revenue (-100.0% YoY), and -498.0% ROE.

Financials · annual, by fiscal year

Line itemFY22FY23FY24FY25
Revenue$284K$686K$7.50K$0.00
Gross profit————
Operating income-$9.45M-$7.45M-$11.0M-$11.0M
Net income-$10.7M-$11.3M-$8.97M-$11.0M
Diluted EPS-$12.74-$54.98-$15.70-$2.25
Net margin-3760.7%-1644.9%-119566.6%—

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$636K
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-405.1%
FCF yield-416.0%

Quality & risk

ROIC (est.)-393.8%
Free cash flow-$11.2M
Total debt—
Net cash$2.07M
Altman Z-Score-24.50 distress
Piotroski F-Score0/7

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+8.1%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Other event2026-06-17
  2. 8-K Charter / bylaws change2026-06-16
  3. 8-K Other event2026-06-04
  4. 8-K Other event2026-05-27
  5. S-1 Securities registration2026-05-21
  6. 8-K Earnings results2026-05-13
  7. 10-Q Quarterly report2026-05-13
  8. DEF 14A Proxy statement2026-05-08
  9. 8-K Material agreement2026-03-23

Recent filings

all on EDGAR ↗
SCHEDULE 13GFiling2026-06-25open ↗SCHEDULE 13DFiling2026-06-24open ↗SCHEDULE 13GFiling2026-06-22open ↗4Period ending 2026-06-162026-06-18open ↗8-KPeriod ending 2026-06-172026-06-17open ↗8-KPeriod ending 2026-06-152026-06-16open ↗DEFA14AFiling2026-06-04open ↗8-KPeriod ending 2026-06-042026-06-04open ↗EFFECTFiling2026-06-02open ↗DEFA14AFiling2026-05-27open ↗8-KPeriod ending 2026-05-272026-05-27open ↗S-1Filing2026-05-21open ↗

Quality score

F
ValueGrowthProfitHealthMom.
Value—
GrowthF
ProfitabilityF
Financial healthB-
Momentum—
  • ✗Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
Revenue
$0.00
-100.0% YoY
Net margin
—
ROE
-498.0%
P/E
—

SEC fundamentals · FY 2025

'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$0.00-100.0%
Net income-$11.0M-22.2%
Operating income-$11.0M+0.2%
Diluted EPS-$2.25+85.7%
Cash & equivalents$2.07M-54.6%
Total assets$5.03M-31.7%
Total liabilities$1.22M-26.3%
Stockholders' equity$2.20M-61.4%
L/E: 0.56x

Frequently asked

Is Azitra, Inc. (AZTR) a buy?
AZTR currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.56x); but revenue fell -100.0% YoY.
What is Azitra, Inc.'s quality score?
AZTR scores 35.46153846153846/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001701478, latest 10-Q filed 2026-05-13) · EODHD · as of 6/22/2026, 11:31:31 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-06-16
Salva Francisco D.
President and CEO
Acquired (C)4.06M

Earnings history

beat/miss · move
2026-05-13Miss -2351.0% est▼ -1.36%8-K ↗
2026-02-27Beat +38.5% est▼ -3.85%8-K ↗
2025-11-12Beat +15.2% est▲ +2.02%8-K ↗
2025-08-11Beat +16.0% est▼ -3.05%8-K ↗
2025-05-13—▼ -2.78%8-K ↗
2025-02-24—▼ -4.35%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Top Biotech Gainers: TNON Files S-1, NVCT Inks License Deal, FTH On Watch, RGNX To Resubmit BLABullish
nasdaq.com· 2026-06-23
Azitra Prices Private Placement To Advance New Cosmetic Protein & Peptide Programs; Stock UpBullish
nasdaq.com· 2026-03-20
Azitra Gets NYSE American Listing Compliance NoticeBearish
nasdaq.com· 2026-03-16
Azitra GAAP EPS of -$2.25 beats by $0.23
seekingalpha.com· 2026-02-27
Azitra reports Q3 resultsBearish
seekingalpha.com· 2025-11-13
Azitra receives notice of non-compliance from NYSE AmericanBearish
seekingalpha.com· 2025-10-03

Vs tracked universe

compare →

1043 tracked peers · median

EDGAR Score35 vs 67
Revenue growth-100.0% vs 7.1%
Net margin— vs 10.5%
Return on equity-498.0% vs 12.3%
P/E— vs 25.5